迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688192 迪哲医药

已收盘 01-10 15:00:00

{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":38.9,"timestamp":1736492400000,"preClose":39.6,"halted":0,"volume":1535139,"delay":0,"changeRate":-0.0177,"floatShares":187000000,"shares":418000000,"eps":-2.0047,"marketStatus":"已收盘","change":-0.7,"latestTime":"01-10 15:00:00","open":39.57,"high":40.4,"low":38.74,"amount":60905800,"amplitude":0.0419,"askPrice":38.9,"askSize":7,"bidPrice":38.88,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-2.0047,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736731800000},"marketStatusCode":5,"adr":0,"adjPreClose":39.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1736472600000,1736479800000],[1736485200000,1736492400000]],"highLimit":43.56,"lowLimit":35.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417648086,"isCdr":false,"pbRate":37.92,"roa":"--","roe":"--","epsLYR":-2.72,"committee":0.520958,"marketValue":16247000000,"turnoverRate":0.0082,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-01-13。","afterMarket":{"amount":0,"volume":0,"close":38.9,"buyVolume":4000,"sellVolume":0,"time":1736494438029,"indexStatus":"已收盘 01-10 15:30:00","preClose":39.6},"floatMarketCap":7263000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2502091627","title":"迪哲医药：舒沃哲®新药上市申请已获FDA受理并被授予优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2502091627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502091627?lang=zh_cn&edition=full","pubTime":"2025-01-09 18:00","pubTimestamp":1736416848,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药01月09日在投资者关系平台上答复投资者关心的问题。如果公司无法准确预估，请公司收集提供FDA过往类似新药可供参考的申请流程及审批时间周期数据，供投资者自行估计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010900030503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2502058889","title":"迪哲医药大涨 舒沃替尼获FDA优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2502058889","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502058889?lang=zh_cn&edition=full","pubTime":"2025-01-09 10:31","pubTimestamp":1736389868,"startTime":"0","endTime":"0","summary":"消息解读迪哲医药披露公告称，其自主研发的新型肺癌靶向药舒沃替尼片的新药上市申请已通过美国食品药品监督管理局的立卷审查，并被授予优先审评资格。资金动向截止发稿，迪哲医药-U获得主力净流出583万元，其中超大单流出329万元，大单流出252万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109103130a21af696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109103130a21af696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2502387500","title":"迪哲医药（688192）5745.18万股限售股将于1月9日解禁，占总股本13.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502387500","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502387500?lang=zh_cn&edition=full","pubTime":"2025-01-09 08:04","pubTimestamp":1736381065,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于1月9日将有5745.18万股限售股份解禁，为公司首发原股东限售股份，占公司总股本13.76%。最近一年内，该股累计解禁617.8万股，占总股本的1.48%。本次解禁后，公司还有2.31亿股限售股份，占总股本55.29%。迪哲医药主营业务：创新药的研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010900006064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2502208034","title":"26.04亿元市值限售股今日解禁，迪哲医药、秦川机床、九丰能源解禁市值居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2502208034","media":"界面","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502208034?lang=zh_cn&edition=full","pubTime":"2025-01-09 07:39","pubTimestamp":1736379570,"startTime":"0","endTime":"0","summary":"Wind数据显示，周四（1月9日），共有4家公司限售股解禁，合计解禁量为9978.89万股，按最新收盘价计算，合计解禁市值为26.04亿元。从解禁量来看，2家公司解禁股数超千万股。迪哲医药-U、秦川机床、九丰能源解禁量居前，解禁股数分别为5745.18万股、3889.05万股、305.07万股。从解禁市值来看，2家公司解禁股数超亿元。迪哲医药-U、秦川机床、九丰能源解禁市值居前，解禁市值分别为21.95亿元、3.23亿元、8133.06万元。从解禁股数占总股本比例来看，1家公司解禁比例超10%。迪哲医药-U、秦川机床、九丰能源解禁比例居前，解禁比例分别为13.76%、3.86%、0.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109073930aba3be9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109073930aba3be9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0061","BK0009","605090","BK0130","688192","BK0259","BK0252","000837"],"gpt_icon":0},{"id":"2501476992","title":"迪哲医药-U 强势上涨获增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2501476992","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501476992?lang=zh_cn&edition=full","pubTime":"2025-01-08 09:39","pubTimestamp":1736300343,"startTime":"0","endTime":"0","summary":"01月08日，迪哲医药-U股价大幅上涨，截至09点39分，迪哲医药-U上涨5.27%，报39.72元/股，成交2406万元，换手率0.48%，振幅5.09%。资金动向截止发稿，迪哲医药-U获得主力净流入75万元，其中超大单流入4万元，大单流入71万元。主营业务及业绩迪哲医药-U公司主营业务为创新药物的研发和产业化，高度重视员工的创新研发能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010809392995fc2141&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010809392995fc2141&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2501222809","title":"迪哲医药：舒沃替尼上市申请获FDA优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2501222809","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501222809?lang=zh_cn&edition=full","pubTime":"2025-01-07 16:36","pubTimestamp":1736239002,"startTime":"0","endTime":"0","summary":"每经AI快讯，迪哲医药(688192)1月7日晚间公告，公司自主研发的舒沃替尼片（商品名：舒沃哲®，简称“舒沃替尼”）新药上市申请已通过美国食品药品监督管理局（FDA）的立卷审查，并被授予优先审评资格，用于既往经含铂化疗治疗时或治疗后出现疾病进展，且经FDA批准的试剂盒检测确认，存在表皮生长因子受体（EGFR）20号外显子插入突变（Exon20ins）的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者。文章来源：每日经济新闻原标题：迪哲医药：舒沃替尼上市申请获FDA优先审评资格","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107163930aba189d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107163930aba189d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2501091221","title":"迪哲医药：舒沃替尼上市申请获美国FDA受理并取得优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2501091221","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501091221?lang=zh_cn&edition=full","pubTime":"2025-01-07 16:19","pubTimestamp":1736237957,"startTime":"0","endTime":"0","summary":"迪哲医药公告，公司自主研发的舒沃替尼片新药上市申请已通过美国FDA的立卷审查，并被授予优先审评资格，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认存在EGFR 20号外显子插入突变的局部晚期或转移性非小细胞肺癌的成人患者。舒沃哲是全球唯一获批治疗EGFR Exon20ins NSCLC的口服小分子靶向药。FDA的“优先审评资格”主要授予在治疗、诊断或预防某些严重疾病方面取得重大安全性或有效性突破的药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010700026654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2501226537","title":"迪哲医药(688192.SH)：舒沃替尼上市申请获美国FDA受理并取得优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2501226537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501226537?lang=zh_cn&edition=full","pubTime":"2025-01-07 15:44","pubTimestamp":1736235897,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，公司自主研发的舒沃替尼片(商品名：舒沃哲®，简称“舒沃替尼”)新药上市申请(NDA)已通过美国食品药品监督管理局(FDA)的立卷审查，并被授予优先审评资格，用于既往经含铂化疗治疗时或治疗后出现疾病进展，并且经FDA批准的试剂盒检测确认，存在表皮生长因子受体(EGFR)20号外显子插入突变(Exon20ins)的局部晚期或转移性非小细胞肺癌(NSCLC)的成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"迪哲医药(688192.SH)：舒沃替尼上市申请获美国FDA受理并取得优先审评资格","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2500439883","title":"【下周A股解禁市值超335亿元】数据显示，下周A股市场将有45家公司限售股陆续解禁，合计解禁数量为20.23亿股，以最新收盘价计算，合计解禁市值达到335.55亿元。其中1月6日是解禁高峰期，共有14家公司面临限售股解禁，合计解禁市值超过222亿元，占下周解禁规模比例近70%。按最新收盘价计算，下周解禁市值位居前三的分别是中国移动、迪哲医药-U、陆家嘴，解禁市值分别为164.44亿元、22.98亿元、20.98亿元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500439883","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500439883?lang=zh_cn&edition=full","pubTime":"2025-01-04 22:28","pubTimestamp":1736000925,"startTime":"0","endTime":"0","summary":"数据显示，下周A股市场将有45家公司限售股陆续解禁，合计解禁数量为20.23亿股，以最新收盘价计算，合计解禁市值达到335.55亿元。其中1月6日是解禁高峰期，共有14家公司面临限售股解禁，合计解禁市值超过222亿元，占下周解禁规模比例近70%。按最新收盘价计算，下周解禁市值位居前三的分别是中国移动、迪哲医药-U、陆家嘴，解禁市值分别为164.44亿元、22.98亿元、20.98亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/04222847132777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1328615791.USD","600941","600663","LU0516422440.USD","LU1497734951.SGD","LU0871576103.HKD","LU0039217434.USD","BK0053","LU0516422952.EUR","BK1506","LU1634259391.SGD","LU1226288253.USD","SGXZ81163826.USD","80883","LU1481107354.HKD","BK0273","LU1064131003.USD","CHL","BK1152","SGXZ49509284.SGD","BK0239","00941","BK0187","LU1226288170.HKD","LU1634259557.SGD","BK0261","159982","LU1226287875.USD","BK0188","BK0012","LU0149721374.USD","LU0164865239.USD","LU1951186391.HKD","BK0196","688192","LU0164880469.USD","BK0011","LU0531971595.HKD","LU1226287792.SGD","BK0184","LU0516423091.SGD","LU1522347837.USD","LU1497733557.USD","BK1521","LU1064130708.USD","LU1497733631.SGD","BK1536","LU1226287529.USD","399300","BK0028"],"gpt_icon":0},{"id":"2500436296","title":"下周A股解禁市值超335亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500436296","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500436296?lang=zh_cn&edition=full","pubTime":"2025-01-04 22:26","pubTimestamp":1736000779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1226287529.USD","LU1497733631.SGD","LU1064131003.USD","LU1522347837.USD","BK0188","688192","BK0261","00941","CHL","LU1634259391.SGD","BK0187","600663","BK1536","BK0053","BK1589","LU0516422366.SGD","LU1497734951.SGD","LU1951186391.HKD","159982","LU1328615791.USD","LU0531971595.HKD","BK0196","LU1226288253.USD","LU0516423091.SGD","SGXZ49509284.SGD","BK1152","BK0239","LU0516423174.USD","LU0149721374.USD","80883","LU1226288170.HKD","LU1064130708.USD","LU1497733557.USD","600941","LU1634259557.SGD","LU0039217434.USD","SGXZ81163826.USD","BK0011","LU1226287792.SGD","LU2148510915.USD","LU0164880469.USD","399300","LU0516422440.USD","LU1481107354.HKD","SG9999002463.SGD","BK0012","LU0516422952.EUR","BK0028","LU0871576103.HKD","LU0164865239.USD"],"gpt_icon":0},{"id":"2500319682","title":"国办：审评审批资源向临床急需重点创新药和医疗器械倾斜","url":"https://stock-news.laohu8.com/highlight/detail?id=2500319682","media":"北京商报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500319682?lang=zh_cn&edition=full","pubTime":"2025-01-03 18:49","pubTimestamp":1735901344,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 王寅浩）1月3日，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（以下简称《意见》）。《意见》提出，要完善审评审批机制全力支持重大创新。按照“提前介入、一企一策、全程指导、研审联动”要求，审评审批资源更多向临床急需的重点创新药和医疗器械倾斜，在临床试验、注册申报、核查检验、审评审批等全过程加强沟通交流，提供个性化指导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688575","603987","688131","688520","BK0251","688338","600763","159883","603733","688767","603590","603205","600080","688578","688656","601089","688621","159992","688607","603087","603583","603301","688193","600829","688687","688161","688799","688389","688212","688013","688580","688710","688176","688289","600998","605369","688358","688075","688050","688192","688166","688278","688314","688302","600135","688067","603976","688331","688356","688468","BK0239","688606","688382"],"gpt_icon":0},{"id":"2495016692","title":"迪哲医药5745万限售股将于2025年1月9日流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2495016692","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495016692?lang=zh_cn&edition=full","pubTime":"2024-12-31 20:46","pubTimestamp":1735649160,"startTime":"0","endTime":"0","summary":"财中社12月31日电迪哲医药 发布首次公开发行部分限售股上市流通公告。此次上市流通的限售股总数为5745万股，占公司总股本的13.76%。根据公告，限售股将于2025年1月9日起上市流通，锁定期为自公司股票上市之日起3个完整会计年度。公告还提到，公司的总股本由4亿股变更为4.18亿股，主要由于2020年员工股份期权计划行权和2022年限制性股票激励计划的归属所致。整体来看，公司的股本数量在限售股上市流通前未发生其他变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-31/doc-ineckkxt1814804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2495662014","title":"迪哲医药(688192.SH)约5745.18万股限售股将于1月9日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2495662014","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495662014?lang=zh_cn&edition=full","pubTime":"2024-12-31 18:21","pubTimestamp":1735640477,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，本次上市流通的限售股为公司首次公开发行前部分股东持有的限售股，涉及1名限售股股东，为江苏无锡迪喆企业管理合伙企业有限合伙)简称“无锡迪喆”)，持有限售股份约5745.18万股，占公司目前股本总数的13.76%。限售期为自公司股票上市之日起3个完整会计年度。现锁定期即将届满，上述限售股将于2025年1月9日起上市流通。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1231790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2494123208","title":"迪哲医药（688192）617.8万股限售股将于12月27日解禁，占总股本1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494123208","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494123208?lang=zh_cn&edition=full","pubTime":"2024-12-27 08:03","pubTimestamp":1735257784,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于12月27日将有617.8万股限售股份解禁，为公司股权激励一般股份,股权激励期权行权，占公司总股本1.48%。本次解禁后，公司还有2.88亿股限售股份，占总股本69.05%。迪哲医药主营业务：创新药的研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122700006085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2494114518","title":"16.09亿元市值限售股今日解禁，威迈斯、汇隆活塞、迪哲医药解禁市值居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2494114518","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494114518?lang=zh_cn&edition=full","pubTime":"2024-12-27 07:38","pubTimestamp":1735256284,"startTime":"0","endTime":"0","summary":"周五，共有11家公司限售股解禁，合计解禁量为1.08亿股，按最新收盘价计算，合计解禁市值为16.09亿元。从解禁量来看，4家公司解禁股数超千万股。汇隆活塞、南京商旅、威迈斯解禁量居前，解禁股数分别为4151.6万股、2647.18万股、1782.51万股。从解禁市值来看，4家公司解禁股数超亿元。威迈斯、汇隆活塞、迪哲医药-U解禁市值居前，解禁市值分别为4.42亿元、3亿元、2.6亿元。从解禁股数占总股本比例来看，2家公司解禁比例超10%。汇隆活塞、无锡晶海、南京商旅解禁比例居前，解禁比例分别为23.4%、15.03%、8.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227074527a20b0804&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241227074527a20b0804&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688612","BK0264","688192"],"gpt_icon":0},{"id":"2494854706","title":"迪哲医药收盘下跌0.26%，最新市净率40.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2494854706","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494854706?lang=zh_cn&edition=full","pubTime":"2024-12-26 20:21","pubTimestamp":1735215719,"startTime":"0","endTime":"0","summary":"12月26日，迪哲医药今日收盘42.05元，下跌0.26%，最新市净率40.99。截至2024年三季报，共有47家机构持仓迪哲医药，其中基金40家、其他6家、QFII1家，合计持股数5546.07万股，持股市值24.30亿元。迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。最新一期业绩显示，2024年三季报，公司实现营业收入3.38亿元，同比743.97%；净利润-558460529.94元，同比32.63%，销售毛利率97.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412262026429850267b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412262026429850267b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2494047540","title":"迪哲医药：股东ZYTZ所持389万股解除质押 占公司总股本比例0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494047540","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494047540?lang=zh_cn&edition=full","pubTime":"2024-12-25 20:50","pubTimestamp":1735131057,"startTime":"0","endTime":"0","summary":"中国财富通12月25日 - 迪哲医药（688192）公告称，股东ZYTZ Partners Limited持有公司股份5,167,283股，占公司总股本的1.24%。公司近日接到ZYTZ的通知，获悉其所持有本公司的部分股份已经办理解除质押手续，ZYTZ本次解除质押股份3,890,000股，占其持股数量的75.28%，占公司总股本的0.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=DCIKMPyNglg%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2494011334","title":"迪哲医药股东ZYTZ解除质押389万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2494011334","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494011334?lang=zh_cn&edition=full","pubTime":"2024-12-25 15:53","pubTimestamp":1735113180,"startTime":"0","endTime":"0","summary":"财中社12月25日电迪哲医药（688192）发布公告，股东ZYTZ解除质押股份389万股，占其持股的75.28%及公司总股本的0.93%；截至公告披露日，ZYTZ已无质押股份。2024年前三季度，迪哲医药-U实现收入3.38亿元，归母净利润-5.58亿元。（文章来源：财中社）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122515572495ec1dc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122515572495ec1dc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2494097765","title":"中航证券给予迪哲医药买入评级：深耕恶性肿瘤，源头创新构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2494097765","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494097765?lang=zh_cn&edition=full","pubTime":"2024-12-25 13:56","pubTimestamp":1735106169,"startTime":"0","endTime":"0","summary":"中航证券12月25日发布研报称，给予迪哲医药买入评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225135912a20898e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225135912a20898e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688192","161027"],"gpt_icon":0},{"id":"2494097589","title":"中航证券：给予迪哲医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2494097589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494097589?lang=zh_cn&edition=full","pubTime":"2024-12-25 13:50","pubTimestamp":1735105826,"startTime":"0","endTime":"0","summary":"中航证券有限公司李蔚近期对迪哲医药进行研究并发布了研究报告《深度报告：深耕恶性肿瘤，源头创新构建全球竞争力》，本报告对迪哲医药给出买入评级，当前股价为42.09元。舒沃哲由于分子量小，可突破血脑屏障，基线伴脑转移患者同样获得临床收益，mPFS达5.5个月。我们预计公司2024-2026年的EPS分别为-1.88元、-1.40元和-0.01元，给予买入评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为58.64。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122500019658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","161027"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":-0.1686},{"period":"3month","weight":-0.0627},{"period":"6month","weight":-0.048},{"period":"1year","weight":-0.1346},{"period":"ytd","weight":-0.062}],"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","perCapita":"21605股","boardName":"医药制造业","registeredCapital":"41764万元","compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.0153},{"period":"6month","weight":0.0664},{"period":"1year","weight":0.0976},{"period":"ytd","weight":-0.0547}],"survey":"　　迪哲(江苏)医药股份有限公司主营业务是创新药物的研发、生产和销售，公司主要产品及服务为舒沃替尼、戈利昔替尼、DZD8586、DZD2269、DZD1516等。公司研发管线均为小分子创新药，所有产品均享有全球权益，并采用全球同步开发的模式。","serverTime":1736598993636,"listedPrice":52.58,"stockholders":"8642人(较上一季度增加1.99%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}